Nuclear Medicine and Molecular Imaging

  • 제42권2호
  • /
  • Pages.164-171
  • /
  • 2008
  • /
  • 1869-3474(pISSN)
  • /
  • 1869-3482(eISSN)
대한핵의학회 (The Korean Society of Nuclear Medicine)
권호 표지

방사선 내부흡수선량의 의학적 적용

Medical Application of Radiation Internal Dosimetry

  • 김경민 (한국원자력의학원 방사선의학연구소 분자영상연구부) ;
  • 임상무 (한국원자력의학원 방사선의학연구소 분자영상연구부)
  • Kim, Kyeong-Min (Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences) ;
  • Lim, Sang-Moo (Molecular Imaging Research Center, Korea Institute of Radiological and Medical Sciences)
  • 발행 : 2008.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Medical internal radiation dosimetry (MIRD) is an important part of nuclear medicine research field using therapeutic radioisotope. There have been many researches using MIRD for the development of new therapeutic approaches including radiopharmaceutical, clinical protocol, and imaging techniques. Recently, radionuclide therapy has been re-focused as new solution of intractable diseases, through to the advances of previous achievements. In this article, the basic concepts of radiation and internal radiation dosimetry are summarized to help understanding MIRD and its application to clinical application.

키워드

참고문헌

  1. Turner JH, Martindale AA, Boucek J, Claringbold PG, Leahy MF. $^{131}I$-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biother Radiopharm 2003;18:513-24 https://doi.org/10.1089/108497803322287583
  2. Wiseman GA, Kornmehl E, Leigh B, Erwin WD, Podoloff DA, Spies S, et al. Radiation dosimetry results and safety correlations from $^{90}Y$-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 2003;44:465-74
  3. Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculation. New York: The Society of Nuclear Medicine; 1988
  4. 김은실, 김종순, 김은희. 방사선 안전관리. 고창순 편저. 핵의학. 제2판. 서울: 고려의학; 1997. p. 235-51
  5. 임상무, 홍성운. 방사성의약품 치료. 고창순 편저. 핵의학. 제2판. 서울: 고려의학; 1997. p.767-98
  6. Internal radiation dosimetry. In: Cherry SR, Sorenson JA, Phelps ME. editors. Physics in Nuclear Medicine. 3rd ed. Philadelphia: Saunders; 2003. p.405-25
  7. Sgouros G. Dosimetry of internal emitters. J Nucl Med. 2005;46: 18S-27S
  8. Macey DJ, williams LE, Breitz HB. Liu A, Johnson TK, Zanzonico PB. AAPM report No. 17: a primer for radioimmunotherapy and radionuclide therapy. American Association of Physicists in Medicine; 2001
  9. Macey DJ, williams LE, Breitz HB. Liu A, Johnson TK, Zanzonico PB. AAPM report No. 17: a primer for radioimmunotherapy and radionuclide therapy. American Association of Physicists in Medicine; 2001
  10. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 1999;40:37S-61S
  11. Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, Howell RW, et al. MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions--radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med 1999;40:11S-36S
  12. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the secondgeneration personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005;46:1023-7
  13. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-46
  14. Rajendran JG, Fisher DR, Gopal AK, Durack LD, Press OW, Eary JF. High-dose $^{131}I$-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's lymphoma: adjusting radiation absorbed dose to actual organ volumes. J Nucl Med 2004;45:1059-64
  15. Behr TM, Griesinger F, Riggert J, Gratz S, Behe M, Kaufmann CC, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti- CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002;94:1363-72 https://doi.org/10.1002/cncr.10307
  16. Menzel C, Grunwald F, Schomburg A, Palmedo H, Bender H, Spath G, et al. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 1996;37:1496-503
  17. Mayer A, Tsiompanou E, Flynn AA, Pedley RB, Dearling J, Boden R, et al. Higher dose and dose-rate in smaller tumors result in improved tumor control. Cancer Invest 2003;21:382-8 https://doi.org/10.1081/CNV-120018229
  18. DeNardo SJ, Williams LE, Leigh BR, Wahl RL. Choosing an optimal radioimmunotherapy dose for clinical response. Cancer 2002;94:1275-86 https://doi.org/10.1002/cncr.10297
  19. Erwin WD, Groch MW, Macey DJ, DeNardo GL, DeNardo SJ, Shen S. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol 1996;23:525-32 https://doi.org/10.1016/0969-8051(96)00036-4
  20. Zanzonico P, Sgouros G. Predicting myelotoxicity in radioimmunotherapy: what does dosimetry contribute? J Nucl Med 1997;38: 1753-4
  21. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998;39:14S-20S
  22. Delpon G, Ferrer L, Lenta C, Lisbona A, Buvat I, Bardies M. Comparison of four scatter correction methods for patient whole-body imaging during therapeutic trials with iodine-131. Cancer 2002; 94(suppl):1224-30 https://doi.org/10.1002/cncr.10289
  23. Zaidi H, Koral KF. Scatter modelling and compensation in emission tomography. Eur J Nucl Med Mol Imaging 2004;31:761-82 https://doi.org/10.1007/s00259-004-1495-z
  24. Leichner PK, Koral KF, Jaszczak RJ, Green AJ, Chen GT, Roeske JC. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys 1993;20: 569-77 https://doi.org/10.1118/1.597051
  25. Dewaraja YK, Ljungberg M, Koral KF. Monte Carlo evaluation of object shape effects in iodine-131 SPET tumor activity quantification. Eur J Nucl Med 2001;28:900-6 https://doi.org/10.1007/s002590100551
  26. Dewaraja YK, Ljungberg M, Koral KF. Characterization of scatter and penetration using Monte Carlo simulation in $^{131}I$ imaging. J Nucl Med 2000;41:123-30
  27. Macey DJ, Grant EJ, Bayouth JE, Giap HB, Danna SJ, Sirisriro R, Podoloff DA. Improved conjugate view quantitation of I-131 by subtraction of scatter and septal penetration events with a triple energy window method. Med Phys 1995;22:1637-43 https://doi.org/10.1118/1.597423
  28. Koral KF, Zasadny KR, Ackermann RJ, Ficaro EP. Deadtime correction for two multihead Anger cameras in $^{131}I$ dual-energy window-acquisition mode. Med Phys 1998;25:85-91 https://doi.org/10.1118/1.598162
  29. Furhang EE, Chui CS, Kolbert KS, Larson SM, Sgouros G. Implementation of a Monte Carlo dosimetry method for patientspecific internal emitter therapy. Med Phys 1997;24:1163-72 https://doi.org/10.1118/1.598018
  30. Yoriyaz H, Stabin MG, dos Santos A. Monte Carlo MCNP-4B-based absorbed dose distribution estimates for patient-specific dosimetry. J Nucl Med 2001;42:662-9
  31. Furhang EE, Chui CS, Sgouros G. A Monte Carlo approach to patient-specific dosimetry. Med Phys 1996;23:1523-9 https://doi.org/10.1118/1.597882
  32. Kolbert KS, Sgouros G, Scott AM, Bronstein JE, Malane RA, Zhang J, et al. Implementation and evaluation of patient-specific threedimensional internal dosimetry. J Nucl Med 1997;38:301-8
  33. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med 1993;34:689-94
  34. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioac-- tivity concentration in blood and body. J Nucl Med 1999;40:2102-6
  35. Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison. J Nucl Med 2004;45:1725-33
  36. Behr TM, Behe M, Sgouros G. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings. Cancer Biother Radiopharm 2002;17:445-64 https://doi.org/10.1089/108497802760363231
  37. Sgouros G, Stabin M, Erdi Y, Akabani G, Kwok C, Brill AB, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys 2000;27:2150-64 https://doi.org/10.1118/1.1288393